Ascentage Pharma Receives IND Clearance in China for APG-3288, a BTK Degrader Targeting Hematologic Malignancies

Ascentage Pharma has received clearance for its Investigational New Drug (IND) application from the China Center for Drug Evaluation (CDE) for APG-3288, a novel Bruton’s Tyrosine Kinase (BTK) degrader. The approval allows the company to initiate clinical trials of APG-3288 in China, marking a significant step in the development of this potential therapeutic agent.

APG-3288 is designed as a BTK degrader, targeting diseases associated with abnormal BTK activity. Bruton’s Tyrosine Kinase plays a critical role in B-cell receptor signaling and is implicated in various hematologic malignancies and autoimmune disorders. With this IND clearance, Ascentage Pharma plans to proceed with clinical studies to evaluate the safety and efficacy of APG-3288. This development aligns with the company’s focus on advancing innovative therapies for unmet medical needs.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 5, 2026

Author

GOAI